Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.36 |
| ▸ | BMP1 | P13497 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10246744 | 0.88 | SLC7A5 (0.42) | SLC7A5L3MBTL1TDP1RAB9ABMP1 | |
| SCHEMBL3420016 | 0.85 | L3MBTL1 (0.50) | SLC7A5L3MBTL1TDP1RAB9ACYP4F2 | |
| SCHEMBL2776077 | 0.83 | L3MBTL1 (0.41) | L3MBTL1TDP1RAB9ACYP4F2CYP4A11 | |
| SCHEMBL2776081 | 0.83 | L3MBTL1 (0.41) | L3MBTL1TDP1RAB9ACYP4F2CYP4A11 | |
| SCHEMBL406657 | 0.81 | SLC7A5 (0.40) | SLC7A5L3MBTL1TDP1RAB9AKDM1A | |
| SCHEMBL10246740 | 0.81 | SLC7A5 (0.40) | SLC7A5L3MBTL1TDP1RAB9AKDM1A | |
| SCHEMBL406656 | 0.81 | SLC7A5 (0.40) | SLC7A5L3MBTL1TDP1RAB9AKDM1A | |
| SCHEMBL2184610 | 0.78 | CTSB (0.42) | — | |
| SCHEMBL9968906 | 0.77 | SLC7A5 (0.40) | SLC7A5L3MBTL1TDP1RAB9AF2 | |
| SCHEMBL14101267 | 0.77 | TDP1 (0.46) | L3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
| WO-2009043889-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240658-A1 | Oxadiazole Derivatives | OXA1L, RO60, NQO2 | SLC7A5 4631/4885L3MBTL1 3352/4885TDP1 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.